Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …

G Martinelli, I Iacobucci, S Soverini… - Hematological …, 2006 - Wiley Online Library
Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …
被引用次数：42 相关文章

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …

G Martinelli, I Iacobucci, S Soverini… - Hematological …, 2006 - pubmed.ncbi.nlm.nih.gov
Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

[引用][C] Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …

G Martinelli, I Iacobucci, S Soverini, D Cilloni… - HEMATOLOGICAL …, 2006 - iris.unina.it
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid
leukaemia patients in treatment with imatinib as a guide to clinical management IRIS IRIS Home …

Monitoring minimal residual disease and controlling drug resistance in chronicmyeloid leukaemia patients in treatment with imatinib as a guide to clinicalmanagement.

G Martinelli, I Iacobucci, S Soverini, D Cilloni… - HEMATOLOGICAL …, 2006 - cris.unibo.it
Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

[引用][C] Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …

G Martinelli, I Iacobucci, S Soverini, D Cilloni… - … CLINICS OF NORTH …, 2006 - iris.unito.it
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid
leukaemia patients in treatment with imatinib as a guide to clinical management IRIS IRIS Home …

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …

G Martinelli, I Iacobucci, S Soverini, D Cilloni… - Hematological …, 2006 - europepmc.org
Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …